What is he best known for?
The fields of study he is best known for:
Ivan D. Horak spends much of his time researching Immunology, Molecular biology, Cancer research, Interleukin 2 and Immune system.
He integrates many fields, such as Immunology and Gene mutation, in his works.
His Cancer research research is multidisciplinary, incorporating perspectives in Haematopoiesis and Transcription factor.
His Interleukin 2 research includes themes of T cell, Lymphocytic choriomeningitis, B cell, Vesicular stomatitis virus and Autoimmunity.
His Immune system research includes elements of Cytotoxic T cell, CD40, Antibody and Antigen.
The study incorporates disciplines such as Colitis, Inflammatory bowel disease and Ulcerative colitis in addition to Antigen.
His most cited work include:
- Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. (1574 citations)
- Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. (789 citations)
- Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. (569 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Molecular biology, Cancer research, Immunology, Antibody and In vivo.
As a part of the same scientific family, Ivan D. Horak mostly works in the field of Molecular biology, focusing on Transfection and, on occasion, Oligonucleotide, Locked nucleic acid and Cell biology.
His research on Cancer research also deals with topics like
- Transcription factor together with Interferon,
- Pathology and related Radioimmunotherapy, Carcinoembryonic antigen and Pretargeting.
His study in Immune system, Interleukin 2, Immunoglobulin G, Cytokine and B cell is done as part of Immunology.
His research in Immune system is mostly focused on T cell.
His research investigates the connection between Antibody and topics such as Cell culture that intersect with problems in Recombinant DNA.
He most often published in these fields:
- Molecular biology (29.19%)
- Cancer research (20.50%)
- Immunology (23.60%)
What were the highlights of his more recent work (between 2009-2019)?
- Cancer research (20.50%)
- Molecular biology (29.19%)
- In vivo (12.42%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Molecular biology, In vivo, Internal medicine and Pharmacology.
Ivan D. Horak incorporates Cancer research and Syngeneic mouse in his research.
His Molecular biology study integrates concerns from other disciplines, such as Cancer, Prostate, Transfection and Locked nucleic acid, Oligonucleotide.
He has included themes like Protein kinase B and Cell biology in his Transfection study.
His work in Oncology addresses issues such as Immunity, which are connected to fields such as Antibody.
His Antibody research focuses on subjects like Longevity, which are linked to Cell culture.
Between 2009 and 2019, his most popular works were:
- ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis (60 citations)
- Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. (55 citations)
- Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor (53 citations)
In his most recent research, the most cited papers focused on:
Ivan D. Horak mainly investigates Pharmacology, Cancer research, Lapatinib, PI3K/AKT/mTOR pathway and Camptothecin.
Ivan D. Horak has researched Pharmacology in several fields, including Downregulation and upregulation, Western blot, Signal transduction and Transcription factor.
In his works, Ivan D. Horak performs multidisciplinary study on Cancer research and Vincristine.
In his papers, Ivan D. Horak integrates diverse fields, such as Lapatinib, Gefitinib, Cell growth, Tyrosine kinase, Akt/PKB signaling pathway and Kinase activity.
Ivan D. Horak interconnects Carcinogenesis, Protein kinase B, Growth inhibition and Proto-oncogene tyrosine-protein kinase Src in the investigation of issues within PI3K/AKT/mTOR pathway.
His Camptothecin research integrates issues from Angiogenesis, Chorioallantoic membrane, Matrigel, Glioma and MMP2.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
